Eric P. Winer
A5070245248- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Cancer Risks and Factors
- Cancer survivorship and care
- Global Cancer Incidence and Screening
- Breast Lesions and Carcinomas
- Lung Cancer Research Studies
- PI3K/AKT/mTOR signaling in cancer
- DNA Repair Mechanisms
- Economic and Financial Impacts of Cancer
- Radiopharmaceutical Chemistry and Applications
- Fibroblast Growth Factor Research
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
Dana-Farber Cancer Institute
2016-2025
Harvard University
2016-2025
CancerCare
2017-2025
Yale University
2022-2025
Dana-Farber/Harvard Cancer Center
2006-2025
Yale Cancer Center
2009-2025
Dana-Farber Brigham Cancer Center
2015-2024
Hartford Financial Services (United States)
2024
New School
2024
Broad Institute
2014-2024
Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)–paclitaxel may enhance the anticancer activity of atezolizumab.
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer.An American Society Clinical Oncology (ASCO) Expert Panel conducted systematic review literature available through February 2004 on SNB early-stage cancer. The panel developed clinicians and patients regarding appropriate lymph identification sampling procedure from hereon referred to as SNB. was reviewed by selected experts field ASCO Health Services Committee approved Board Directors.The...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) negative human epidermal growth factor 2 (HER2).In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy safety selective CDK4/6 inhibitor ribociclib combined with letrozole first-line treatment 668 postmenopausal women HR-positive, HER2-negative recurrent metastatic who had...
Purpose: Using a 2 × factorial design, we studied the adjuvant chemotherapy of women with axillary node–positive breast cancer to compare sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) concurrent (AC) followed by (T) for disease-free (DFS) overall survival (OS); determine whether dose density agents improves DFS OS; toxicities. Patients Methods: A total 2,005 female patients were randomly assigned receive one following regimens: (I) 4 (doses) → T C doses every 3 weeks,...
Abstract BACKGROUND Women with HER‐2 overexpressing metastatic breast carcinoma benefit from trastuzumab‐based therapy, but trastuzumab does not cross the blood‐brain barrier. The authors characterized central nervous system (CNS) disease in these women. METHODS Using pharmacy records, retrospectively identified 153 women treated alone or chemotherapy for HER‐2–positive at Dana‐Farber Partners Cancer Care June 1998 to December 2000. A study cohort of 122 patients was after excluding without...
Purpose To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Patients Methods Between July 1994 February 1999, 636 (age years) who had clinical stage I (T1N0M0 according TNM classification) estrogen receptor (ER) –positive carcinoma treated by lumpectomy were randomly assigned receive plus (TamRT; 317 women) or alone (Tam; 319 women). Primary end points time local regional...
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy multiple HER2-targeted agents limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. We randomly assigned patients HER2-positive previously treated trastuzumab, pertuzumab, and trastuzumab emtansine, had or did not brain metastases, to receive either tucatinib placebo, in combination...
In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen as effective followed by radiation therapy.Between July 1994 and February 1999, we randomly assigned 636 were had clinical stage I (T1N0M0 according to the tumor-node-metastasis classification), estrogen-receptor-positive carcinoma treated receive therapy (317 women) alone (319 women). Primary end points time local regional recurrence, frequency mastectomy for...
Abstract Brain metastases are associated with a dismal prognosis. Whether brain harbor distinct genetic alterations beyond those observed in primary tumors is unknown. We performed whole-exome sequencing of 86 matched metastases, tumors, and normal tissue. In all clonally related cancer samples, we branched evolution, where metastatic sites shared common ancestor yet continued to evolve independently. 53% cases, found potentially clinically informative the not detected primary-tumor sample....
PURPOSE Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As DNA cross-linking agent, cisplatin may be effective treatment hereditary BRCA1-mutated cancers. Because sporadic triple-negative (TNBC) and BRCA1-associated share features suggesting common pathogenesis, we conducted neoadjuvant trial of in TNBC explored specific biomarkers to identify predictors response. PATIENTS AND METHODS Twenty-eight women with stage II or III cancers lacking estrogen...
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 × factorial, open-label, randomized phase II trial, evaluated the impact adding carboplatin and/or bevacizumab.Patients (N = 443) stage to III TNBC received paclitaxel 80 mg/m(2) once per week (wP) for 12 weeks, followed by doxorubicin plus cyclophosphamide every weeks (ddAC) four cycles, and were randomly assigned...
PURPOSE: Approximately 40,000 men die each year of hormone-refractory prostate cancer (HRPC). The results treatment with chemotherapy have been disappointing to date, no trials demonstrating a benefit respect survival duration. Corticosteroids and mitoxantrone shown be active agents in this disease. purpose study was demonstrate an advantage hydrocortisone (M+H) over alone PATIENTS AND METHODS: Two hundred forty-two patients HRPC were randomized receive either M+H or alone. Patients...
Purpose Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first reported 2005. One of these reports, the joint North Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab Treating Women HER2-Overexpressing Breast Cancer) and National Surgical Adjuvant Bowel Project NSABP B-31 (Doxorubicin Cyclophosphamide...
BRCA1/2-mutated and some sporadic triple-negative breast cancers (TNBC) have DNA repair defects are sensitive to DNA-damaging therapeutics. Recently, three independent DNA-based measures of genomic instability were developed on the basis loss heterozygosity (LOH), telomeric allelic imbalance (TAI), large-scale state transitions (LST).We assessed a combined homologous recombination deficiency (HRD) score, an unweighted sum LOH, TAI, LST scores, in neoadjuvant TNBC trials platinum-containing...
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies content in 0.1× coverage whole-genome data without prior knowledge mutations. We apply ichorCNA to 1439 samples 520 patients with metastatic prostate or breast cancers. In earliest tested sample for each patient, 34% have ≥10% tumor-derived cfDNA, sufficient...